Your Destination for TCT 2022 Resources On-Demand: Watch Now

AMI Cardiogenic Shock

Clinical Evidence

Key Findings from the National Cardiogenic Shock Initiative Study ^1,2,3

Identify and support cardiogenic shock early
Aggressive down titration of inotropes
Identify inadequate left ventricular (LV) support and escalate, if CPO <0.6
Identify right ventricular (RV) dysfunction early and support
Systematically use right heart catheter (RHC) to guide therapy

Impella® Clinical Evidence Pathway to Class I Recommendation

Impella clinical evidence has established safety and effectiveness and validated best practices.

Ongoing and Upcoming Clinical Trials

RECOVER IV Randomized Controlled Trial

Upcoming trial to assess whether Impella pre-PCI is superior to PCI without Impella in patients with AMI cardiogenic shock.

DanGer Shock Randomized Controlled Trial

Ongoing trial assessing primary outcome of death from all causes at six months with Impella CP® compared to standard of care.

The Procedure

Learn more about femoral access explant techniques and other best practices.

References

Tehrani, B.N., et al. (2019). JACC, 73, 1659-1669.
Basir, M.B., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183.
O’Neill, W.W., (2020). TCT Connect 2020

NPS-1187